Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes —a Pediatric Nephrology Research Consortium study
ConclusionsThis multi-center retrospective cohort analysis indicates that a significant number of children and young adults are being exposed to C5 blockade for off-label indications. Dosing schedules were highly variable, limiting outcome conclusions. Attributable adverse events appeared to be low. Cohort mortality (6.6%) was not insignificant. Prospective studies in homogenous disease cohorts are needed to support the role of C5 blockade in kidney outcomes.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
More News: Children | Gastroenteritis | Genetics | Glomerulonephritis | Hemolytic Uremic Syndrome (HUS) | Men | Meningitis | Pediatrics | Statistics | Study | Urology & Nephrology